Compare · ANVS vs NVO
ANVS vs NVO
Side-by-side comparison of Annovis Bio Inc. (ANVS) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ANVS and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $179.89B, about 1622.2x ANVS ($110.9M).
- Over the past year, ANVS is up 30.2% and NVO is down 36.1% - ANVS leads by 66.3 points.
- NVO has been more active in the news (6 items in the past 4 weeks vs 5 for ANVS).
- NVO has more recent analyst coverage (25 ratings vs 4 for ANVS).
- Company
- Annovis Bio Inc.
- Novo Nordisk A/S
- Price
- $1.94+5.15%
- $42.44+5.35%
- Market cap
- $110.9M
- $179.89B
- 1M return
- -12.61%
- +15.50%
- 1Y return
- +30.20%
- -36.13%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2020
- News (4w)
- 5
- 6
- Recent ratings
- 4
- 25
Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest ANVS
- Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
- Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
- SEC Form 424B5 filed by Annovis Bio Inc.
- Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
- The Credibility Filter Wall Street Uses to Sort Biotech Winners
- SEC Form 4 filed by Hoffman Michael B
- Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
- Annovis Publishes Historical Review of Buntanetap in The Scientist
- Annovis Bio Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S